DE69717308D1 - Verwendung von cntf (ciliary neurotrophic factor) rezeptoraktivatoren fur behandlung von fettleibigkeit - Google Patents
Verwendung von cntf (ciliary neurotrophic factor) rezeptoraktivatoren fur behandlung von fettleibigkeitInfo
- Publication number
- DE69717308D1 DE69717308D1 DE69717308T DE69717308T DE69717308D1 DE 69717308 D1 DE69717308 D1 DE 69717308D1 DE 69717308 T DE69717308 T DE 69717308T DE 69717308 T DE69717308 T DE 69717308T DE 69717308 D1 DE69717308 D1 DE 69717308D1
- Authority
- DE
- Germany
- Prior art keywords
- obesity
- cntf
- treatment
- neurotrophic factor
- ciliary neurotrophic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2264—Obesity-gene products, e.g. leptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT96RM000790A IT1288388B1 (it) | 1996-11-19 | 1996-11-19 | Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia |
PCT/IT1997/000283 WO1998022128A1 (en) | 1996-11-19 | 1997-11-18 | Use of cntf (ciliary neurotrophic factor) receptor activators for the treatment of obesity |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69717308D1 true DE69717308D1 (de) | 2003-01-02 |
DE69717308T2 DE69717308T2 (de) | 2003-07-10 |
Family
ID=11404538
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69717308T Expired - Lifetime DE69717308T2 (de) | 1996-11-19 | 1997-11-18 | Verwendung von cntf (ciliary neurotrophic factor) rezeptoraktivatoren fur behandlung von fettleibigkeit |
Country Status (14)
Country | Link |
---|---|
US (2) | US6565869B1 (de) |
EP (1) | EP0946189B1 (de) |
JP (1) | JP4067127B2 (de) |
CN (2) | CN102145163B (de) |
AT (1) | ATE228003T1 (de) |
AU (1) | AU727174B2 (de) |
CA (1) | CA2271781C (de) |
DE (1) | DE69717308T2 (de) |
DK (1) | DK0946189T3 (de) |
ES (1) | ES2187830T3 (de) |
IL (2) | IL129968A0 (de) |
IT (1) | IT1288388B1 (de) |
PT (1) | PT946189E (de) |
WO (1) | WO1998022128A1 (de) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6472178B1 (en) | 1998-02-27 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof |
IT1288388B1 (it) | 1996-11-19 | 1998-09-22 | Angeletti P Ist Richerche Bio | Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia |
EP1010432A4 (de) * | 1997-01-23 | 2004-03-10 | Sumitomo Pharma | Heilmittel für diabetes |
IT1291114B1 (it) | 1997-03-20 | 1998-12-29 | Angeletti P Ist Richerche Bio | Varianti del fattore neurotrofico ciliare (cntf) con migliorata selettivita' al recettore, e metodo per la loro selezione |
US6680291B1 (en) | 1998-02-27 | 2004-01-20 | Regeneron Pharmaceuticals, Inc. | Modified ciliary neurotrophic factor, method of making and methods of use thereof |
CA2368431C (en) | 1999-03-29 | 2006-01-24 | The Procter & Gamble Company | Melanocortin receptor ligands |
WO2000063357A2 (en) * | 1999-04-20 | 2000-10-26 | Beth Israel Deaconess Medical Center | Methods and compositions for modulating ciliary neurotrophic factor activity |
IL132312A0 (en) * | 1999-09-05 | 2001-03-19 | Yeda Res & Dev | Use of leptin in inhibition of endothelial cell proliferation |
AU2001230587A1 (en) * | 2000-02-18 | 2001-08-27 | Sumitomo Pharmaceuticals Company, Limited | Drugs for ameliorating impaired glucose tolerance |
WO2001066133A1 (fr) * | 2000-03-06 | 2001-09-13 | Sumitomo Pharmaceuticals Company, Limited | Agents d'amelioration de la resistance a la leptine |
JP2003535831A (ja) * | 2000-05-24 | 2003-12-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 毛様体神経栄養因子の使用 |
WO2001094605A2 (en) * | 2000-06-09 | 2001-12-13 | University Of Florida Research Foundation, Inc. | Recombinant aav vectors for gene therapy of obesity |
CN1494593A (zh) * | 2001-03-02 | 2004-05-05 | Ĭ��ר������˾ | 具有降低免疫原性的经修饰睫状神经营养因子(cntf) |
US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
US20050064555A1 (en) * | 2003-07-09 | 2005-03-24 | Xencor, Inc. | Ciliary neurotrophic factor variants |
WO2005028438A1 (ja) | 2003-09-22 | 2005-03-31 | Banyu Pharmaceutical Co., Ltd. | 新規ピペリジン誘導体 |
EP2305352A1 (de) | 2004-04-02 | 2011-04-06 | Merck Sharp & Dohme Corp. | 5-alpha-Reduktaseinhibitoren zur Behandlung von Stoffwechsel- und anthropometrischen Störungen |
US7279282B2 (en) * | 2004-07-09 | 2007-10-09 | Scott Mellis | Methods for identifying a candidate for treatment of obesity |
EP1814590B2 (de) | 2004-11-01 | 2013-12-11 | Amylin Pharmaceuticals, Inc. | Behandlung von fettsucht und verbundenen erkrankungen |
US8394765B2 (en) | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
ES2574014T3 (es) | 2005-05-30 | 2016-06-14 | Msd K.K. | Derivado de piperidina novedoso |
EP1916239A4 (de) | 2005-08-10 | 2009-10-21 | Banyu Pharma Co Ltd | Pyridolverbindung |
EP1921065B1 (de) | 2005-08-24 | 2010-10-20 | Banyu Pharmaceutical Co., Ltd. | Phenylpyridonderivat |
WO2007029847A1 (ja) | 2005-09-07 | 2007-03-15 | Banyu Pharmaceutical Co., Ltd. | 二環性芳香族置換ピリドン誘導体 |
EP1940842B1 (de) | 2005-09-29 | 2012-05-30 | Merck Sharp & Dohme Corp. | Acylierte spiropiperidinderivate als modulatoren des melanocortin-4-rezeptors |
BRPI0617621A2 (pt) | 2005-10-21 | 2011-08-02 | Novartis Ag | combinação de compostos orgánicos |
AU2006307046A1 (en) | 2005-10-27 | 2007-05-03 | Msd K.K. | Novel benzoxathiin derivative |
MY146564A (en) | 2005-11-10 | 2012-08-30 | Msd Kk | Aza-substituted spiro derivatives |
EP2698157B1 (de) | 2006-09-22 | 2015-05-20 | Merck Sharp & Dohme Corp. | Verfahren zur Behandlung von Fettsäure-Synthese-Hemmern |
WO2008038692A1 (fr) | 2006-09-28 | 2008-04-03 | Banyu Pharmaceutical Co., Ltd. | dÉrivÉ de diarylcÉtimine |
AU2008233662B2 (en) | 2007-04-02 | 2012-08-23 | Msd K.K. | Indoledione derivative |
US7879802B2 (en) | 2007-06-04 | 2011-02-01 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
CA2714617A1 (en) | 2008-03-06 | 2009-09-11 | Banyu Pharmaceutical Co., Ltd. | Alkylaminopyridine derivative |
US20110015198A1 (en) | 2008-03-28 | 2011-01-20 | Banyu Pharmaceutical Co., Inc. | Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism |
EP3239170B1 (de) | 2008-06-04 | 2019-03-20 | Synergy Pharmaceuticals Inc. | Für die behandlung von gastrointestinalen erkrankungen, entzündungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase |
EP2301936A1 (de) | 2008-06-19 | 2011-03-30 | Banyu Pharmaceutical Co., Ltd. | Spirodiamin-diarylketoximid-derivat |
EP3241839B1 (de) | 2008-07-16 | 2019-09-04 | Bausch Health Ireland Limited | Zur behandlung von erkrankungen des magen-darm-trakts, entzündlichen erkrankungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase |
EP2319841A1 (de) | 2008-07-30 | 2011-05-11 | Msd K.K. | (5-gliedriges)-(5-gliedriges) oder (5-gliedriges)-(6-gliedriges) kondensiertes ringcycloalkylaminderivat |
CA2741125A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2010051206A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
US20110243940A1 (en) | 2008-12-16 | 2011-10-06 | Schering Corporation | Bicyclic pyranone derivatives and methods of use thereof |
EP2379547A1 (de) | 2008-12-16 | 2011-10-26 | Schering Corporation | Pyridopyrimidinderivate und verfahren zu deren anwendung |
US8895596B2 (en) | 2010-02-25 | 2014-11-25 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
EP2677869B1 (de) | 2011-02-25 | 2017-11-08 | Merck Sharp & Dohme Corp. | Neue cyclische azabenzimidazolderivate als antidiabetika |
AU2013296470B2 (en) | 2012-08-02 | 2016-03-17 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
AU2014219020A1 (en) | 2013-02-22 | 2015-07-23 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
JP6606491B2 (ja) | 2013-06-05 | 2019-11-13 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼcの超高純度アゴニスト、その作成および使用方法 |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
CN104558148B (zh) * | 2013-10-17 | 2018-11-06 | 北京生物制品研究所有限责任公司 | 睫状神经营养因子突变体及其修饰型突变体和用途 |
JP6769963B2 (ja) | 2014-08-29 | 2020-10-14 | ティエエッセ ファルマ ソチエタ レスポンサビリタ リミタータ | α−アミノ−β−カルボキシムコン酸セミアルデヒド脱炭酸酵素の阻害剤 |
WO2016070419A1 (zh) * | 2014-11-07 | 2016-05-12 | 陕西麦科奥特科技有限公司 | 睫状神经营养因子鼻腔给药系统及其制备方法和应用 |
CN106632650B (zh) * | 2015-10-30 | 2020-11-13 | 北京生物制品研究所有限责任公司 | 睫状神经营养因子突变体及其修饰型突变体和应用 |
AU2017342083A1 (en) | 2016-10-14 | 2019-04-11 | Tes Pharma S.R.L. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
EP3551176A4 (de) | 2016-12-06 | 2020-06-24 | Merck Sharp & Dohme Corp. | Antidiabetische heterocyclische verbindungen |
EP3558298A4 (de) | 2016-12-20 | 2020-08-05 | Merck Sharp & Dohme Corp. | Antidiabetische spirochromanverbindungen |
WO2018128745A1 (en) * | 2017-01-06 | 2018-07-12 | The Board Of Trustees Of The Leland Stanford Junior University | Ciliary neurotrophic factor receptor ligands and methods of using the same |
EP3728315A1 (de) * | 2017-12-18 | 2020-10-28 | Regeneron Pharmaceuticals, Inc. | Bispezifische antigen-bindende moleküle, die leptinrezeptor-androgen oder gp130 binden, und verfahren zu deren verwendung |
CA3104472A1 (en) * | 2018-06-19 | 2019-12-26 | Cella Therapeutics, Llc | Drug delivery systems comprising active pharmaceutical ingredients and a sustained delevery component |
US20210228685A1 (en) * | 2018-07-24 | 2021-07-29 | Bioreg Llc | Improved weight loss therapy |
KR20210111248A (ko) | 2018-11-20 | 2021-09-10 | 테스 파마 에스.알.엘. | α-아미노-β-카르복시뮤콘산 세미알데하이드 데카르복실라제의 저해제 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5166317A (en) | 1988-10-31 | 1992-11-24 | Houston Biotechnology Incorporated | Neurotrophic factor |
US5011914A (en) | 1989-01-05 | 1991-04-30 | Collins Franklin D | Purified ciliary neurotrophic factor |
US5141856A (en) | 1989-01-05 | 1992-08-25 | Synergen, Inc. | Expression of purified ciliary neurotrophic factor |
US4997929A (en) | 1989-01-05 | 1991-03-05 | Synergen, Inc. | Purified ciliary neurotrophic factor |
IE903130A1 (en) | 1989-09-15 | 1991-03-27 | Regeneron Pharma | Ciliary neurotrophic factor |
CN1061623A (zh) | 1990-06-01 | 1992-06-03 | 里珍纳龙药品有限公司 | 睫状神经营养性因子受体 |
CS156891A3 (en) | 1990-06-01 | 1992-04-15 | Regeneron Pharma | Receptor of a cilary neurotropic factor |
US5426177A (en) | 1990-06-01 | 1995-06-20 | Regeneron Pharmaceuticals, Inc. | Ciliary neurotrophic factor receptor |
US5691313A (en) | 1991-07-23 | 1997-11-25 | Amgen Inc. | Methods of treating impotency with ciliary neurotrophic factor |
HUT67352A (en) | 1991-07-23 | 1995-03-28 | Syntex Inc | Recombinant ciliary neurotrophic factor and c-ferminal truncated ciliary neurotrophic factor, their production, and pharmaceutical products for treatment of peripheral nerveinjury, containing them |
US5593857A (en) | 1991-08-23 | 1997-01-14 | Scios Inc. | Production of homogeneous truncated CNTF |
AU2925392A (en) | 1991-11-11 | 1993-06-15 | Fidia S.P.A. | Synthesis and purification of truncated and mutein forms of human ciliary neuronotrophic factor |
US5955290A (en) | 1991-12-02 | 1999-09-21 | Regeneron Pharmaceuticals, Inc. | Assay systems using the CNTF signal transduction pathway |
US5349056A (en) | 1992-10-09 | 1994-09-20 | Regeneron Pharmaceuticals | Modified ciliary neurotrophic factors |
US5470952A (en) | 1993-10-20 | 1995-11-28 | Regeneron Pharmaceuticals, Inc. | CNTF and IL-6 antagonists |
US6143714A (en) | 1994-10-24 | 2000-11-07 | Regeneron Pharmaceuticals, Inc. | Methods of using hepatocyte growth factor to promote survival, growth and differentiation of motor neurons |
IT1284867B1 (it) | 1996-07-10 | 1998-05-22 | Angeletti P Ist Richerche Bio | Varianti del fattore neurotrofico ciliare umano (hcntf) con uno spettro di azione differente dalla molecola di tipo selvatico |
IT1288388B1 (it) | 1996-11-19 | 1998-09-22 | Angeletti P Ist Richerche Bio | Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia |
-
1996
- 1996-11-19 IT IT96RM000790A patent/IT1288388B1/it active IP Right Grant
-
1997
- 1997-11-18 US US09/308,368 patent/US6565869B1/en not_active Expired - Lifetime
- 1997-11-18 WO PCT/IT1997/000283 patent/WO1998022128A1/en active IP Right Grant
- 1997-11-18 DK DK97946043T patent/DK0946189T3/da active
- 1997-11-18 DE DE69717308T patent/DE69717308T2/de not_active Expired - Lifetime
- 1997-11-18 CA CA002271781A patent/CA2271781C/en not_active Expired - Lifetime
- 1997-11-18 CN CN201010282598XA patent/CN102145163B/zh not_active Expired - Lifetime
- 1997-11-18 IL IL12996897A patent/IL129968A0/xx unknown
- 1997-11-18 EP EP97946043A patent/EP0946189B1/de not_active Expired - Lifetime
- 1997-11-18 JP JP52343398A patent/JP4067127B2/ja not_active Expired - Lifetime
- 1997-11-18 PT PT97946043T patent/PT946189E/pt unknown
- 1997-11-18 CN CN2009102210662A patent/CN101703761B/zh not_active Expired - Lifetime
- 1997-11-18 AU AU51344/98A patent/AU727174B2/en not_active Expired
- 1997-11-18 ES ES97946043T patent/ES2187830T3/es not_active Expired - Lifetime
- 1997-11-18 AT AT97946043T patent/ATE228003T1/de active
-
2003
- 2003-01-31 US US10/356,191 patent/US6960558B2/en not_active Expired - Lifetime
-
2005
- 2005-07-26 IL IL12996805A patent/IL129968A/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU727174B2 (en) | 2000-12-07 |
PT946189E (pt) | 2003-02-28 |
CN102145163A (zh) | 2011-08-10 |
ES2187830T3 (es) | 2003-06-16 |
IL129968A (en) | 2005-11-20 |
CA2271781C (en) | 2002-11-12 |
AU5134498A (en) | 1998-06-10 |
EP0946189A1 (de) | 1999-10-06 |
US6960558B2 (en) | 2005-11-01 |
ITRM960790A1 (it) | 1998-05-19 |
JP2000511561A (ja) | 2000-09-05 |
CN102145163B (zh) | 2013-09-18 |
CN101703761A (zh) | 2010-05-12 |
EP0946189B1 (de) | 2002-11-20 |
CN101703761B (zh) | 2013-11-20 |
ATE228003T1 (de) | 2002-12-15 |
US20030176346A1 (en) | 2003-09-18 |
JP4067127B2 (ja) | 2008-03-26 |
DK0946189T3 (da) | 2002-12-16 |
DE69717308T2 (de) | 2003-07-10 |
CA2271781A1 (en) | 1998-05-28 |
WO1998022128A1 (en) | 1998-05-28 |
ITRM960790A0 (it) | 1996-11-19 |
IL129968A0 (en) | 2000-02-29 |
US6565869B1 (en) | 2003-05-20 |
IT1288388B1 (it) | 1998-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE228003T1 (de) | Verwendung von cntf (ciliary neurotrophic factor) rezeptoraktivatoren fur behandlung von fettleibigkeit | |
NO986100D0 (no) | Androgene reseptormodulerende forbindelser og fremgangsmÕter | |
ATE244018T1 (de) | Herstellungb und verwendung eines spezifischen gaba-aalpha5 rezeptorligands zur behandlung der erkrankung von alzheimer | |
DE69829412D1 (de) | Hemmung der raf-kinase unter verwendung von symmetrisch und unsymmetrisch substituierten harnstoffen | |
DE69528475D1 (de) | Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie | |
TR199700644T1 (xx) | Serotonin-ili�kili sistemler �zerinde etkiye sahip bile�ikler. | |
ES2168376T3 (es) | Anticuerpos que activan un receptor de eritropoyetina. | |
DE69616480D1 (de) | Piperidinderivate als neurokininantagonisten | |
DE69809726T2 (de) | Substituierte analoge von indol-3-carbinol und von diindolmethan als antiestrogene | |
DE69536017D1 (de) | Methoden und zusammensetzungen für die behandlung von glomerulonephritis | |
NO972591L (no) | Steroid reseptormodulator-forbindelser og fremgangsmåter | |
DE59814072D1 (de) | Verwendung von Agonisten des zentralen Cannabinoid-Rezeptors CB1 | |
ATE241354T1 (de) | Verwendung von 5-(tetradecyloxy)-2-furan carbonsäure für die behandlung von alzheimer krankheit oder psychosis | |
TR200000930T2 (tr) | Büyüme hormonu sekretagogları. | |
DE69314024D1 (de) | NEUE GABAa-REZEPTORSUBTYPEN UND VERFAHREN ZUM SCREENING VON ARZNEIMITTELVERBINDUNGEN UNTER VERWENDUNG VON GABAa-REZEPTORSUBTYPEN BINDENDE IMIDAZOCHINOXALINE UND PYRROLOPYRIMIDINE | |
TR199800956T1 (xx) | Yeni �ndol-2, 3-diyon-3- oksim t�revleri. | |
DE69524623D1 (de) | Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen | |
ATE113591T1 (de) | 4-benzyl-5-phenyl-2,4-dihydro-3h-1,2,4-triazol- - one und ihre verwendung als antikonvulsiva. | |
DE3751362D1 (de) | 5-Aryl-3H-1,2,4-triazol-3-one und ihre Verwendung als Antikonvulsiva. | |
DE69004924T2 (de) | Therapeutische verwendung von 5-ht3-rezeptor-antagonisten. | |
ATE187442T1 (de) | Tryptamine zur behandlung von störungen der circadianen rhythmik | |
DE69802828D1 (de) | Verwendung von 6,7-substituierter 2-aminotetraline zur behandlung von zytokin-vermittleten entzündungszuständen | |
DE3765250D1 (de) | Verwendung von 24,25-dihydroxycholecalciferol zur behandlung von harnsteinen. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |